In vitro activity of plazomicin compared to other clinically relevant aminoglycosides in carbapenem-resistant Enterobacteriaceae

被引：8
作者：
Clark, Justin A. [1 ]
Kulengowski, Brandon [1 ,2 ]
Burgess, David S. [1 ]
机构：
[1] Univ Kentucky, Coll Pharm, Lexington, KY 40506 USA
[2] UK Healthcare, Albert B Chandler Hosp, Lexington, KY USA
来源：
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE | 2020年 / 98卷 / 02期
关键词：
Carbapenem-resistant Enterobacteriaceae; Plazomicin; Aminoglycoside resistance; Susceptibility testing;
D O I：
10.1016/j.diagmicrobio.2020.115117
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
We evaluated the in vitro activity of plazomicin against other aminoglycosides in 122 clinical carbapenem-resistant Enterobacteriaceae isolates using several clinical susceptibility breakpoints. Plazomicin had excellent in vitro activity with 98% overall susceptibility. Amikacin was the next most active with 86% overall susceptibility. This dropped to 55% when switching from Clinical Laboratory and Standards Institute to US Committee on Antimicrobial Susceptibility Testing breakpoints. (C) 2020 Elsevier Inc. All rights reserved.
引用
收藏
页数：3
相关论文
共 17 条
[1]  
[Anonymous], 2020, Testing Breakpoint Tables for Interpretation of MICs and Zone Diameters
[2]  
Bhavnani S, 2016, ID WEEK
[3]  
Bhavnani SM., 2018, IDWEEK
[4]   In vitro activity of Plazomicin against Enterobacteriaceae isolates carrying genes encoding aminoglycoside-modifying enzymes most common in US Census divisions [J].
Castanheira, Mariana ;
Davis, Andrew P. ;
Serio, Alisa W. ;
Krause, Kevin M. ;
Mendes, Rodrigo E. .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2019, 94 (01) :73-77
[5]   Activity of plazomicin compared with other aminoglycosides against isolates from European and adjacent countries, including Enterobacteriaceae molecularly characterized for aminoglycoside-modifying enzymes an other resistance mechanisms [J].
Castanheira, Mariana ;
Deshpande, Lalitagauri M. ;
Woosley, Leah N. ;
Serio, Alisa W. ;
Krause, Kevin M. ;
Flamm, Robert K. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2018, 73 (12) :3346-3354
[6]  
Chantell C, 2019, MR02 CLSI
[7]  
CLSI, 2018, CLSI standard M02, V13th
[8]   Aminoglycoside Resistance The Emergence of Acquired 16S Ribosomal RNA Methyltransferases [J].
Doi, Yohei ;
Wachino, Jun-ichi ;
Arakawa, Yoshichika .
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2016, 30 (02) :523-+
[9]   Association between the Presence of Aminoglycoside-Modifying Enzymes and In Vitro Activity of Gentamicin, Tobramycin, Amikacin, and Plazomicin against Klebsiella pneumoniae Carbapenemase-and Extended-Spectrum-β-Lactamase-Producing Enterobacter Species [J].
Haidar, Ghady ;
Alkroud, Ammar ;
Cheng, Shaoji ;
Churilla, Travis M. ;
Churilla, Bryce M. ;
Shields, Ryan K. ;
Doi, Yohei ;
Clancy, Cornelius J. ;
Hong Nguyen, M. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (09) :5208-5214
[10]   Effect of increasing meropenem MIC on the killing activity of meropenem in combination with amikacin or polymyxin B against MBL- and KPC-producing Enterobacter cloacae [J].
Kulengowski, Brandon ;
Rutter, W. Cliff ;
Campion, Jeffrey J. ;
Lee, Grace C. ;
Feola, David J. ;
Burgess, David S. .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2018, 92 (03) :262-266
12